Cara Therapeutics (CARA) PT Raised to $27 at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
Cara Therapeutics Announces Positive Results From Phase 2 Trial in Uremic Pruritus
July 23, 2015 7:01 AM EDTNovel peripheral kappa opioid I.V. CR845 achieved statistically-significant results on primary endpoint of reducing worst itch intensity
Trial demonstrated statistically significant results on secondary endpoint of quality of life improvements with additional positive trend on itch-related sleep disturbances
I.V. CR845 found to be safe and well-tolerated in dialysis patients
Conference call today at 8:30 a.m. ET to discuss results and next steps
SHELTON, Conn., July 23, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biotechnology company focused on developing and... More
